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Myc and Mammary Cancer: Myc is a Downstream Effector
of the ErbB2 Receptor Tyrosine Kinase
Nancy E. Hynes1,3 and Heidi A. Lane2
The proto-oncogene c-myc encodes a transcription factor which plays a major role in the regu-
lation of normal cellular proliferation and is aberrantly expressed in many breast tumors. In a
normal cell Myc expression levels are tightly regulated being subject to many layers of control.
Errantly expressed Myc collaborates with other oncogenes to promote transformation. In this
review we will focus on the association between abnormal Myc expression and mammary
cancer. In particular, we will discuss the role of Myc as a downstream effector of the ErbB2
receptor tyrosine kinase which is overexpressed and constitutively activate in many mammary
tumors. The cooperation between Myc and ErbB2 in transformation will be discussed in rela-
tion to clinical studies on Myc in human cancer and with consideration of transgenic models
of Myc-induced mammary cancer. Data from our laboratory will be presented showing that
deregulated ErbB2 activity strongly stimulates cytoplasmic signaling pathways which in turn
impinge on Myc at multiple levels causing its deregulated expression.
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INTRODUCTION
Cancer arises as a result of cumulative alter-
ations in the genetic make-up of somatic cells. Such
alterations principally lead to the aberrant expres-
sion, mutation or deletion of proteins involved in the
modulation of intracellular pathways governing nor-
mal cellular proliferation and differentiation. These
defects allow cancer cells to evade signals eminat-
ing from their external environment or from internal
checkpoint controls through deregulation of signaling
pathways which normally keep cell proliferation and
survival tightly controlled. In this context, the proto-
oncogene c-myc, which encodes a transcription fac-
tor playing a major role in the regulation of normal
cell proliferation, is abberantly expressed in many hu-
man cancers. Indeed, taking breast cancer as an ex-
ample, c-myc amplification was one of the first consis-
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tent genetic alterations discovered in primary human
tumors (1).
Myc is a member of the bHLHZip4 family of tran-
scription factors which, when dimerized with its part-
ner Max, binds to specific DNA sequences resulting
in the transcriptional regulation of target genes in-
volved in the control of cellular growth/proliferation
[reviewed (2 – 8)]. All known biological effects of Myc,
including the ability to transform cells, result from its
activity as a transcription factor. It has been proposed
that Myc acts as a sensor of the cellular environment
(9), able to trigger proliferation and, in stress situa-
tions, apoptosis. Furthermore, when deregulated, Myc
4 Abbreviations: epidermal growth factor (EGF); receptor tyro-
sine kinase (RTK); phosphatidylinositol-30 kinase (PI3K); endo-
plasmic reticulum (ER); mitogen-activated protein kinase (MAP
kinase); basic helix-loop-helix zipper (bHLHZip); Myc Box II
(MbII); transactivation/transformation-domain associated pro-
tein (TRRAP); histone acetyltransferase (HAT); histone deacety-
lase (HDAC); human mammary epithelial cells (HMEC); human
telomerase catalytic subunit (hTERT); cyclin-dependent kinase
inhibitor (CKI); monoclonal antibody (mAb); mouse mammary
tumor virus (MMTV); whey acidic protein (WAP); transforming
growth factor fi (TGFfi).
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has characteristics which would clearly contribute to
its transforming ability; including its ability to drive
cells through the G1/S-transition of the cell cycle as
well as connections between Myc and the induction
of genomic instability.
In this short review we have focused on the
connection between aberrant Myc expression and
mammary tumorigenesis. Emphasis is placed on the
biological activities of Myc, clinical studies address-
ing Myc deregulation in human breast cancer and
the application of transgenic models of Myc-induced
mammary cancer. Additionally, based on our own ex-
perimentation, the role of Myc as a downstream ef-
fector of the ErbB2 receptor tyrosine kinase (RTK)
will be discussed (10,11). ErbB2 is activated due to
gene amplification and overexpression in a high per-
centage of human breast tumors. Through antibody-
mediated downregulation of ErbB2 receptor signal-
ing pathways in ErbB2-overexpressing breast tumor
cell lines, we suggest that a major downstream effector
contributing to the potentiation of ErbB2-dependent
tumor cell proliferation is Myc. This model will be
discussed in relation to clinical aspects of the impact
of Myc and ErbB2 deregulation in mammary carcino-
genesis, and the application of ErbB2-directed tumor-
specific therapies.
BIOLOGICAL ACTIVITIES OF Myc
Myc, A Key Regulator of Proliferation
and Apoptosis
Myc has a central role in normal cellular
growth/proliferation control. This is most dramati-
cally demonstrated by the observation that expression
of exogenous Myc in quiescent fibroblasts induces S-
phase entry in the absence of growth factors (12).
Furthermore, Myc-negative fibroblasts proliferate at
a slower rate and exhibit reduced expression of G1 cell
cycle regulators (9). Myc has been suggested to act as
an environmental sensor, coordinating adjustment of
cell cycle progression to the external milieu by affect-
ing cell cycle regulators at multiple levels (9). Con-
sistent with a role in proliferation c-myc transcription
is low in resting or differentiated cells, is rapidly in-
duced following mitogenic stimulation and is required
for continuous cellular proliferation (4,5). In the case
of the mammary gland, similar fluctuations in c-myc
RNA levels are observed; reflecting the proliferation
index of the gland. Indeed, the c-myc promoter is a tar-
get for peptide growth factors and for estrogen (4,13),
both of which contribute to proliferation of the gland.
Myc mRNA levels increase during pregnancy-related
proliferation (14). In addition to elevated expression
during pregnancy, increases in Myc expression may
also be important during the proliferative changes
which occur in the breast during the menstrual cycle
(15). In contrast, Myc is not detected during lactation
(14), reflecting the differentiated state of the gland at
this time.
A second distinctive characteristic of Myc is its
ability to induce apoptosis. This was discovered fol-
lowing growth factor-withdrawal from cells ectopi-
cally expressing Myc. In this case, DNA synthesis oc-
curred, but cells failed to multiply and apoptosis was
accelerated (16). It is now known that deregulated
Myc expression sensitizes cells to diverse proapop-
totic stimuli [reviewed (17)]. Indeed, it has been sug-
gested that a cell is constantly poised to enter apop-
tosis and requires stimuli, either intracellular or from
the external environment, in order to survive and pro-
liferate (17). In order for tumor cells to proliferate in
the presence of deregulated Myc expression, there-
fore, additional genetic alterations must occur, which
would allow the malignant cells to circumvent pro-
apoptotic stimuli. It should also be mentioned here
that Myc probably plays a role in regulated apopto-
sis occurring under normal physiological conditions.
In this context, during murine mammary gland invo-
lution following pup withdrawal, c-myc RNA levels
have been observed to increase (13). It is tempting to
speculate, therefore, that this upregulation is linked
to the massive apoptosis which occurs during this de-
velopmental stage.
Myc the Transcription Factor
Myc is a member of the bHLHZip family of tran-
scription factors, possessing a C-terminal DNA bind-
ing domain and a N-terminal transactivation domain.
Myc dimerization with its partner Max is essential
for DNA binding to a consensus site, the so-called
E-box, and transcriptional regulation of target genes.
The N-terminus of Myc contains two highly conserved
regions, the Myc box (Mb) I and II domains. All
biological properties of Myc, including those asso-
ciated with transformation, require its DNA bind-
ing domain and dependent upon the cellular context,
the N-terminal MbI and/or MbII domains, making
it probable that Myc exercises its biological effects
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Fig. 1. A model of the contrasting functions of Myc/Max and Mad/Max dimers. Myc/Max dimers activate transcription via recruitment of
TRRAP and a HAT to the consensus E-box found in target genes. Mad/Max dimers oppose Myc function via recruitment of a multisubunit
complex containing HDAC to the same E-box (see text and Ref. 19 for further details).
through modulation of target gene expression. The
MbII domain binds the nuclear cofactor TRRAP (18),
which in turn recruits the HAT hGCN5 (19). Recruit-
ment of this chromatin remodeling complex to the
DNA by Myc provides an explanation for Myc/Max
induced transcriptional activation. Myc/Max activ-
ity is opposed by Max, when dimerized with one
of the Mad family members. Mad proteins bind a
complex containing co-repressors and HDACs (2,3).
Since Mad/Max dimers and Myc/Max dimers rec-
ognize the same DNA sequence, a very simplistic
model proposes that Mad-Max dimers, via recruit-
ment of HDACs, antagonize the transcriptional ac-
tivity of HAT-associated Myc-Max complexes (19)
(Fig. 1). A final point to consider is that the balance of
the respective dimers may determine Myc target gene
expression, particularly as Myc is expressed in prolif-
erating cells and is down-regulated in differentiated
cells, while the opposite tends to be true for the Mad
family members (5). Myc and Mad1 protein expres-
sion have been examined in normal human breast and
in progressive breast disease, where this correlation
was observed. Mad1 expression was high in differen-
tiated cells and decreased in high-grade tumors, while
the inverse was observed for Myc levels (20).
A comprehensive understanding of the mecha-
nism underlying Myc’s biological activities will arise
from the identification of Myc target genes. These
have remained rather elusive, despite intense study,
for various reasons. However, the general consensus is
that the identified targets reflect Myc’s functions and
can be catagorized as targets involved in growth con-
trol and apoptosis, including among others: hEST2,
the catalytic subunit of telomerase; p19Arf, the tumor
suppressor; thymidine kinase, involved with DNA
metabolism; and lactate dehydrogenase-A, a partici-
pant in anaerobic glycolysis. For a detailed discussion
of Myc targets and their identification, the reader is
referred to recent reviews (2,3). Meaningful for the
discussion of our results (see later), is the fact that
important cell cycle regulators, such as the D-type cy-
clins, are transcriptionally regulated by Myc (21,22).
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Myc AND MAMMARY CANCER
Mechanisms Leading to Deregulated Myc
Expression in Cancer
In a normal cell c-myc transcription is tightly con-
trolled and dependent upon proliferative stimuli. Fur-
thermore, c-myc mRNA and Myc protein are both
short-lived [reviewed (4)]. Thus, in a normal cell Myc
expression is highly regulated, at all possible levels.
In sharp contrast to this, deregulated Myc expres-
sion is quite prevalent in human tumors. Deregu-
lation arises through diverse mechanisms, including
c-myc amplification in solid tumors, and transloca-
tions in leukemias (23). One of the first genetic al-
terations reported in human breast tumors was c-myc
amplification (1). Since then, c-myc amplification has
been extensively studied and the current consen-
sus is that it occurs in approximately 20% of all
breast cancer cases [reviewed (24)]. However, exam-
ination of c-myc mRNA in a relatively small num-
ber of breast tumors by RT-PCR has suggested that
c-myc overexpression does not necessarily arise from
gene amplification (25). Although the mechanism
was not further examined, the results are not supris-
ing considering that Myc expression is controlled
by transcriptional as well as post-transcriptional
mechanisms.
Myc protein levels are also tightly regulated. Mu-
tations within c-myc occur in a high percentage of
Burkitt’s and other lymphomas (26). It has recently
been shown that some of these mutations lead to sta-
bilization of the Myc protein, preventing its destruc-
tion by ubiquitin-mediated proteolysis (27). Stabiliz-
ing Myc mutations have not been reported in breast
cancers. However, Myc protein levels are also con-
trolled by cytoplasmic signaling pathways which are
often deregulated in breast tumor cells. In this con-
text, two pathways which are highly activated due
to overexpression of the RTK ErbB2 in breast tu-
mors are the PI3K and MAP kinase pathways. In-
triguingly, the PI3K pathway has been implicated in
the translational induction of Myc (28), and high MAP
kinase activity promotes an increase in the stabil-
ity of Myc protein (29). Considering that the ulti-
mate level of Myc protein is subject to so many lay-
ers of control and that tumor cells have alterations
in many signaling pathways which impact on this, it
would not be suprising to find that Myc expression
is deregulated in the vast majority of human breast
cancers.
Myc Expression in Primary Breast Tumors
Clinical studies on primary human breast cancer
are valuable not only for predicting patient progno-
sis but also provide clues about tumor biology. It is
generally agreed that there is an association between
c-myc amplification and poor prognosis in breast can-
cer [discussed (23,24,30)]. An immunohistochemical
study on Myc expression in breast tumors revealed
that during tumor progression from well differenti-
ated, low-grade to poorly differentiated, high-grade,
Myc expression increased significantly (20). Very in-
teresting in light of our results, described later, is the
recent report that coamplification of c-erbB2 and c-
myc strongly correlates with a reduction in patient
survival in a series of breast cancer patients (31). This
suggests a certain level of cooperation between dereg-
ulation of these two proteins in breast tumor devel-
opment.
How Does Myc Contribute to Breast
Cancer Development?
Myc deregulation induces inappropriate prolifer-
ation, as evidenced by the ability of Myc to drive some
quiescent cell lines into S-phase (12). This character-
istic might contribute to cancer, not only by keep-
ing cells cycling, i.e., preventing differentiation, but
also by contributing to genomic instability. Deregu-
lated Myc expression has been associated with gene
amplification and karyotypic abnormalities in cul-
tured cells (32,33) and with abnormal ploidy in in
vivo models (34). Altered Myc expression acceler-
ates the passage of cells through G1 into S-phase and
has also been shown to allow cells to pass through
mitotic checkpoints (35). Indeed, a comparison be-
tween A1N4 immortalized human mammary epithe-
lial cells and A1N4 cells expressing exogenous Myc
revealed that, while EGF-withdrawal caused a G1 ar-
rest in both cell lines, EGF readdition induced pre-
mature entry into S-phase in the Myc-expressing cells
(36). Additionally, expression of hTERT, a transcrip-
tional target of Myc (37) has been demonstrated to be
induced following ectopic expression of Myc in non-
immortalized HMEC cultures. This is associated with
increased telomerase activity in these HMECs, which
may in part be responsible for the reported extended
life-span of these cultures (37).
These characteristics of Myc have the potential
to contribute to tumorigenesis by influencing cellular
senescence and/or allowing cells with chromosomal
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abnormalities or damaged DNA to replicate. Whether
these effects reflect expression of very specific target
genes, such as hTERT, or are due to overall effects
on chromatin structure and ensuing gene expression,
leading for example to chromosomal instability, re-
mains to be elucidated (2).
Mouse Models for Myc-Induced Mammary Cancer
Transgenic mouse models have been developed
in order to study the role of Myc in mammary trans-
formation. Myc expression has been targeted to the
mammary gland through the use of several specific
promoters, including WAP and MMTV [reviewed
(38,39)]. These mouse models have clearly demon-
strated that deregulated Myc expression does indeed
induce tumor formation in the mammary gland. How-
ever, in each Myc transgenic strain so far examined,
the females display a long latency and a dependency
upon passage through pregnancy for mammary tu-
mor development. This characteristic is shared with
most mammary-specific tumor models, reflecting the
fact that a single oncogene is generally unable to in-
duce a full tumor phenotype. The necessity for mice
to pass through pregnancy before tumor development
might be explained by the upregulation of the mam-
mary specific promoters driving the transgene, as well
as by the enhanced proliferation at this developmen-
tal stage, which may potentiate selection of additional
mutations.
In order to test for oncogenic cooperativity, Myc
transgenics have been crossed with mice express-
ing other oncogenes, including TGFfi, Ha-Ras and
Bcl-2. TGFfi, a member of the EGF-related family of
peptide growth factors, binds the ErbB1/EGF recep-
tor and induces activation of EGF receptor dimers
and ErbB2-containing heterodimers (40). In human
breast cancer there is often coexpression of the EGF
receptor and TGFfi or one of the other EGF-related
ligands, which leads to autocrine receptor activation
(41,42). As observed for Myc transgenics, there was
also a requirement for pregnancy and an extended tu-
mor latency in the transgenic strains expressing TGFfi
in the mammary gland. In striking contrast, how-
ever, tumorigenesis in dual transgene carriers (coex-
pressing TGFfi and Myc in the mammary gland) was
dramatically enhanced (38,39,43–45). Furthermore,
the double transgenic mice developed mammary tu-
mors rapidly in all glands without a requirement
for pregnancy or ovarian hormone stimulation (44).
These results suggest that there is strong cooperativity
between Myc and the ligand-activated EGF receptor
in promoting mammary cancer.
Offspring arising from the cross of MMTV-Myc
and MMTV-Ras transgenic strains also developed
mammary tumors more rapidly than either of the sin-
gle transgenic strains (46). Interestingly, tumor cells
arising from MMTV-Myc mice showed a different cell
cycle distribution in comparison to cells from tumors
of the MMTV-Ras mice or the dual transgene carriers.
In the Myc tumor cells there was a significant reduc-
tion in the G1 fraction, compared to the cells taken
from the Ras or dual transgene-induced tumors, and
this was accompanied by an increase in the S-phase
fraction (47). These observations accurately reflect
the results seen in the A1N4-Myc cells discussed ear-
lier (36), suggesting that mammary cells with deregu-
lated Myc generally progress rapidly through G1.
As previously mentioned, Myc expression in the
absence of growth factors often leads to apopto-
sis. Taking this in mind, the rapid tumor formation
observed in the dual transgenics might in part be
due to enhanced survival of Myc-expressing cells in
glands with elevated levels of TGFfi. In support of
this proposition, examination of mammary tumors
arising in double and single transgenics for apop-
totic nuclei revealed that there was less apoptosis in
the dual transgene carriers, coexpressing TGFfi and
Myc, than in Myc transgenics (43). Furthermore, when
cells from the tumors coexpressing TGFfi and Myc
were cultured in the presence of an EGF receptor in-
hibitor, apoptosis was elevated (43). Tumors arising
from transgenics coexpressing Myc and Ras also dis-
played a reduced rate of apoptosis when compared
to Myc transgenics (47). These results suggest that
deregulated Myc expression in the mammary gland
promotes a high level of apoptosis. Only when path-
ways emanating from activated growth factor recep-
tors are stimulated, is apoptosis reduced, allowing for
the rapid onset of tumors.
Bcl-2, a pro-survival member of the Bcl-2 fam-
ily, is able to inhibit apoptosis arising from a wide
variety of insults, including deregulated Myc expres-
sion (48,49). Bcl-2 overexpression in the mammary
gland, driven from a WAP-Bcl-2 transgene, was in-
sufficient to induce mammary tumors (50). However,
when these mice were crossed with Myc transgenics,
accelerated development of Myc-induced tumor for-
mation was observed. This was accompanied by a re-
duction in the fraction of apoptotic cells in the dual
transgenic glands, when compared to glands express-
ing Myc alone (50). These results, as well as those
discussed before, suggest that Myc’s ability to induce
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mammary cancer is enhanced upon suppression of its
apoptotic activity. This can be achieved by various
mechanisms, including increased expression of pro-
survival members of the Bcl-2 family or increased
activity of ErbB RTKs. However, it is quite likely
that the cooperativity between Myc and TGFfi goes
beyond the ability of this peptide growth factor to
suppress Myc-induced apoptosis. This supposition is
based on the fact that tumor latency was shorter in
the Myc/TGFfi dual transgenics as compared to the
Myc/Bcl-2 transgenics (44,50). This situation possibly
relates to the observation that ErbB receptor activa-
tion impinges on multiple cellular pathways, whereas
in comparison Bcl-2 has a relatively limited biological
activity.
Equally relevant for this discussion are the phe-
notypes of dual transgenics coexpressing TGFfi and
ErbB2 in the mammary epithelium. These mice also
display an accelerated rate of tumorigenesis in com-
parison to mice expressing a single transgene (51).
Thus, co-expression of TGFfi with either Myc or
ErbB2 leads to accelerated tumorigenesis. It is, there-
fore, of great interest to examine the tumors arising
in the TGFfi-ErbB2 coexpressors. Based upon the re-
sults discussed later, showing that Myc is an effector
of oncogenic ErbB2, one prediction would be that the
mammary tumors arising in the dual TGFfi-ErbB2
transgenics would have elevated levels of Myc expres-
sion. Taken together, these results from transgenic
mice suggest that the mammary epithelium is particu-
larly sensitive to deregulated expression of both ErbB
RTKs and Myc; both of which are overexpressed in
human breast cancer.
Myc as an Effector of Oncogenic ErbB2
Together with c-myc, amplification of the c-erbB2
gene, leading to overexpression of the receptor, was
one of the initial genetic alterations found in breast tu-
mors (52,53). Today there is a wealth of clinical data
demonstrating the importance of ErbB2, and other
members of the ErbB family, in breast cancer. It is now
clear that ErbB2 overexpression correlates with more
aggressive tumor types and a worse patient prognosis
(for reviews on this subject, the interested reader is re-
ferred to: 41,42,54,55). However, despite the obvious
involvement of ErbB2 in breast tumor malignancy,
the underlying mechanisms by which overexpression
of this receptor potentiates tumor cell proliferation
have remained poorly understood. In order to ad-
dress the question of how ErbB2 overexpression con-
tributes to the deregulated proliferation characteris-
tics of tumors, we have used a strategy which allows
efficient down-regulation of the receptor: intracellu-
lar expression of an ErbB2-specific single chain anti-
body (scFv-5R). Specific targeting of scFv-5R to the
ER results in retention of ErbB2 in this compartment,
leading to loss of receptor function (56). Using ErbB2-
overexpressing SKBr3 breast tumor cells, inducible
expression of scFv-5R was demonstrated to result in
the loss of plasma membrane-localized ErbB2. Con-
comitant with this loss of functionally active ErbB2,
there was a dramatic downregulation of ErbB3 activ-
ity and the MAP kinase and PI3K pathways, culmi-
nating in accumulation of the cells in the G1 phase of
the cell cycle (11). Notably, the expression of Myc pro-
tein and mRNA was also decreased in the absence of
ErbB2 signaling. Furthermore, ectopic expression of
Myc partially overcame the scFv-5R-imposed G1 ac-
cumulation, indicating that Myc is a primary effector
of ErbB2-mediated oncogenicity. A closer look at the
mechanisms underlying reductions in Myc expression
following ErbB2 downregulation, revealed that both
Myc mRNA levels and protein stability were affected
(11). As mentioned previously, the PI3K pathway is
involved in the translational induction of Myc (28)
and MAP kinase activation stabilizes the Myc pro-
tein (29). Taken together, therefore, our results sug-
gest that enhanced ErbB2 signaling acts at multiple
points to ensure that Myc levels remain elevated in
breast tumor cells (Fig. 2).
Detailed analyses of cell cycle regulators in scFv-
5R expressing SKBr3 cells revealed an important role
for Myc in ErbB2-overexpressing cells. Specifically,
the G1 block induced by ErbB2 downregulation was
demonstrated to be a consequence of redistribution
of the CKI p27Kip1 from sequestering complexes to cy-
clin E/Cdk2, resulting in cyclin E/Cdk2 inactivation.
This redistribution was found to parallel the decrease
in Myc and cyclin D protein levels (11). It is well es-
tablished that the D-type cyclins as well as Myc play
major roles in the regulation of p27Kip1 complex for-
mation (57). On the one hand, Myc stimulates D-type
cyclin expression at the transcriptional level (21,22)
and, on the other hand, the stability/activation of cy-
clin D-dependent Cdks is in turn facilitated by inter-
action with p27Kip1 (57). It has also been proposed
that other, as yet unknown, p27Kip1 sequestration pro-
teins may be downstream of Myc (58) (“x” in Fig. 2).
Our results revealed that ectopic expression of Myc
in scFv-5R expressing SKBr3 cells delayed the accu-
mulation of these cells in G1. This phenomenon corre-
lated with enhanced cyclin D expression, inhibition of
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Fig. 2. A model of Myc as a downstream effector of oncogenic ErbB2. In breast tumor cells overexpressing ErbB2 there is activation of both
ErbB2 and ErbB3, presumably resulting from concentration-dependent ErbB2 dimerization and lateral activation of ErbB3 (62). Dimers
of ErbB2/ErbB3 are responsible for strong activation of the MAPK and PI3K cytoplasmic signaling pathways. Both pathways contribute to
enhanced expression of the cell cycle regulators Myc and D-type cyclins, two proteins involved in p27Kip1 complex formation. Upon loss of
ErbB2 signaling, either following intracellular expression of scFv-5R or treatment of cells with mAb 4D5, the MAPK and PI3K cytoplasmic
signaling pathways are down-regulated. This leads to a decrease in the level of Myc and the D-type cyclins. Myc stimulates D-type cyclin
expression transcriptionally (21,22), however, the level of D-type cyclins is also controlled by the PI3K cytoplasmic signaling pathway (63).
It has also been proposed that other, as yet unknown, p27Kip1 sequestration proteins may be downstream of Myc (58) (indicated by “x”).
Taken together, the drop in Myc and D-cyclin levels allows the redistribution of p27Kip1 onto cyclinE/cdk2 and concomitant loss of kinase
activity and G1 block (see text for further details).
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p27Kip1 redistribution to cyclin E/Cdk2 complexes and
maintenance of cyclin E/Cdk2 activity. These obser-
vations, therefore, add further weight to the proposal
that elevated Myc activity plays a major role in ErbB2-
dependent breast tumor proliferation, through the
maintenance of p27Kip1 sequestration proteins.
The clear importance of ErbB2 overexpression
in the potentiation of breast tumor proliferation has
resulted in intense scrutiny of ErbB2 as a target for
tumor-directed therapies. In this respect, a mAb that
targets the extracellular domain of ErbB2 (known
as 4D5) specifically inhibits the in vitro growth of
ErbB2-overexpressing breast tumor cells (59,60). In-
deed, the humanized version of 4D5 (HerceptinTM)
has been validated in the clinic as an ErbB2-directed
therapeutic approach (61). In order to understand
the mechanism(s) underlying the effects of 4D5 on
tumor cell growth, we set out to examine specific ef-
fects on cell cycle regulators in ErbB2-overexpressing
breast tumor cells treated with this mAb (10). 4D5-
mediated down-regulation of ErbB2 signaling led to a
G1 accumulation in two ErbB2-overexpressing breast
tumor cell lines (BT474 and SKBr3). Accumulation
in G1 was preceded by a reduction in Cdk2 activ-
ity. Importantly, this correlated with a reduction in
the expression of Myc and cyclin D proteins, as well
as with an increase in p27Kip1 association with cy-
clin E/Cdk2 complexes; events which were not ob-
served with a noninhibitory control antibody (10). In
BT474 cells, both Myc and D-type cyclin protein levels
dropped rapidly (1–2 hrs) after 4D5 addition, with ki-
netics which slightly preceded the accumulation of the
p27Kip1 protein on cyclin E/Cdk2 complexes and cy-
clin E/Cdk2 inactivation. These data not only strongly
support the previous observations outlined (11), but
also point to the importance of ErbB2-dependent
maintenance of Myc and cyclin D protein levels in
ErbB2-overexpressing tumor cells in the clinical set-
ting, particularly since coamplification of c-erbB2 and
c-myc correlates with poorer survival in breast can-
cer patients (31). Future experiments will be aimed
at establishing the role of Myc in the deregulation of
tumor cell proliferation; specifically as a downstream
effector of elevated ErbB2 receptor activity.
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